一种新型下一代FVIIIa模拟物Mim8具有良好的安全性并显示出强效药效学效应:食蟹猴安全性研究结果
在食蟹猴中开展为期4至26周、剂量0.3至60 mg/kg/周静脉或皮下给药的非临床安全性研究,评估Mim8的安全性及药效学。皮下给药0.3至3 mg/kg/周未见血栓或过度凝血激活,6至20 mg/kg/周组16%动物组织病理学检出血栓相关所见。所有剂量水平均观察到APTT缩短及凝血酶生成增加。
要点
- 皮下给药0.3至3 mg/kg/周持续26周未见血栓或过度凝血激活迹象。
- 6至20 mg/kg/周组16%动物组织病理学检查检出血栓相关所见。
- 所有Mim8剂量水平均观察到APTT缩短和凝血酶生成增加。
核心结论
- 6 mg/kg/周以上剂量观察到的血栓相关所见可能是促凝化合物在凝血功能正常动物中放大的药理反应。
- FX和FIX浓度升高可能是因与Mim8结合导致半衰期延长,但在临床相关暴露水平有限。
- 皮下给药最高3 mg/kg/周(为数倍于预期临床暴露)持续26周产生相关药效学效应,凝血酶生成和APTT可见变化,无血栓或过度凝血激活迹象。
研究设计与样本
- 食蟹猴非临床安全性项目由三项研究组成,持续时间4至26周。
- Mim8剂量范围为0.3至60 mg/kg/周,静脉或皮下给药。
- 处死后进行宏观和微观病理学检查。
主要发现
- Mim8耐受良好,无值得注意的临床观察。
- 皮下给药0.3至3 mg/kg/周未见过度凝血迹象及病理学宏观或微观所见。
- 6至20 mg/kg/周剂量组中16%动物组织病理学检查检出血栓相关所见。
- 观察到FX和FIX浓度呈剂量依赖性升高。
- 所有Mim8剂量水平均观察到APTT缩短及在体外血友病A样条件下凝血酶生成增加。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mim8 is a novel, next-generation factor VIIIa mimetic in development for subcutaneous prophylactic treatment of patients with hemophilia A with and without inhibitors. In vitro and in vivo models indicate that Mim8 has a distinct hemostatic potential. OBJECTIVES: To test the nonclinical safety and pharmacodynamics of Mim8. METHODS: The Mim8 nonclinical safety program in cynomolgus monkeys consisted of three studies of 4-26 weeks in duration with Mim8 doses ranging from 0.3-60 mg/kg/week intravenously or subcutaneously. After sacrifice, macroscopic and microscopic pathological examinations were performed. RESULTS: Mim8 was well tolerated with no noteworthy clinical observations. No signs of excessive coagulation or pathological macroscopic or microscopic findings were observed at doses 0.3-3 mg/kg/week subcutaneous. Thrombosis-related findings were detected during histopathological examination in a small proportion of animals (16%) receiving doses ranging 6-20 mg/kg/week. Dose-dependent increases in factor X (FX) and factor IX (FIX) concentrations were observed. Shortening of activated partial thromboplastin time (APTT) and increased thrombin generation under ex vivo hemophilia A-like conditions were observed at all Mim8 dose levels. CONCLUSIONS: Thrombosis-related findings observed at doses above 6 mg/kg/week Mim8 may have been exaggerated pharmacological reactions to a procoagulant compound in normocoagulant animals. Increases in FX and FIX concentrations could be because of a half-life prolongation due to binding to Mim8, but were limited at clinically relevant exposure levels. Subcutaneous administration of up to 3 mg/kg/week (several fold greater than expected clinical exposure) for 26 weeks resulted in relevant pharmacodynamic effects, observed in thrombin generation and APTT, with no signs of thrombi or excessive coagulation activation.
引用
- Lauritzen B, Bjelke M, Björkdahl O, et al. A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys. J Thromb Haemost. 2022. PMID: 35191180. doi:10.1111/jth.15682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。